Table 3.
Serum levels of linoleic acid and conjugated linoleic acid with SAF and CLA supplementation
| Supplementation Period 1 | Supplementation Period 2 | Trend within Treatment* |
Comparison of Treatments† |
||||
|---|---|---|---|---|---|---|---|
| Baseline (Week 0) |
Δ (week 16 - week 0) |
Baseline (Week 0) |
Δ (week 16 - week 0) |
½(Δ period 1) + ½(Δ period 2) |
P-Value | P-Value | |
| Linoleic Acid (% of total fatty acids) | 0.0889 | ||||||
| SAF | 24.2±0.9 | 2.7±0.9 | 24.2±1.1 | 2.9±1.3 | 2.8±0.8 | 0.0004 | |
| CLA | 23.1±1.2 | 2.9±1.2 | 25.6±0.9 | −1.1±0.9 | 0.9±0.8 | 0.2320 | |
| c9t11-CLA (% of total fatty acids) | < 0.0001 | ||||||
| SAF | 0.8±0.2 | 0.09±0.2 | 0.7±0.2 | −0.02±0.3 | 0.03±0.2 | 0.8387 | |
| CLA | 0.9±0.2 | 0.3±0.3 | 0.6±0.1 | 1.0±0.2 | 0.6±0.2 | < 0.0001 | |
| t10c12-CLA (% of total fatty acids) | |||||||
| SAF | 0.0 | 0.0 | 0.0 | 0.0 | |||
| (0.0, 0.0) | (0.0, 0.0) | (0.0, 0.0) | (0.0, 0.0) | ||||
| CLA | 0.0 | 0.2 | 0.0 | 0.6 | |||
| (0.0, 0.0) | (0.1, 0.4) | (0.0, 0.0) | (0.3, 0.7) | ||||
Subjects were treated with either SAF or CLA for 16 weeks (Supplementation Period 1), and then crossed over to the other treatment for 16 weeks (Supplementation Period 2). Results were derived from tests for orthogonal contrasts used in the mixed-effects model. Values are LSM ± SE, pooled across SAF and CLA groups for linoleic acid and c9t11-CLA. Analysis for t10c12-CLA was done using the Sign test, and data are presented as median (95% CI). Values are expressed as a percentage of total fatty acid content of the serum for each subject.
Within-treatment effect of supplementation periods (final – initial value).
Between-treatment effect (SAF compared with CLA).